EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants

Yunfei Li, Hua Zhang, Hitesh Pandya, Liyan Miao, Fred Reid, Eulalia Jimenez, Muhammad Waqas Sadiq, Rachel Moate, Alejhandra Lei, Xiao-Hong Zhou, Chris Kell, Junjie Ding und 3 weitere

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1391 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Yunfei Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacologist, R&D China, AstraZeneca, Shanghai, China. Hauptthemen laut MEDLINE: Dose-Response Relationship, Drug, Healthy Volunteers, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tozorakimab is a high‐affinity human immunoglobulin G1 monoclonal antibody that neutralizes interleukin (IL)‐33, an IL‐1 family cytokine. This phase 1, single‐center, randomized, double‐blind, placebo‐controlled, single ascending dose study (NCT05070312) evaluated tozorakimab in a healthy Chinese population. Outcomes included the characterization of the pharmacokinetic (PK) profile and immunogenicity of tozorakimab. Safety outcomes included treatment‐emergent adverse events (TEAEs) and clinical laboratory, electrocardiogram, and vital sign parameters. Healthy, non‐smoking, male, and female Chinese participants aged 18‐45 years with a body mass index 19‐24 kg/m 2 were enrolled. In total, 36 participants across 2 cohorts of 18 participants were randomized 2:1 to receive a single subcutaneous dose of tozorakimab (300 mg [2 mL] or 600 mg [4 mL]) or matching placebo (2 or 4 mL). Tozorakimab showed dose‐dependent serum PK concentrations with an approximate monophasic distribution in serum over time and a maximum observed peak concentration of 20.1 and 33.7 μg/mL in the 300‐ and 600‐mg cohorts, respectively. No treatment‐emergent anti‐drug antibodies for tozorakimab were observed in any of the participants. There were no clinically relevant trends in the occurrence of TEAEs across the treatment groups. There were no clinically relevant trends over time in clinical laboratory (hematology, clinical chemistry, and urinalysis), electrocardiogram, or vital sign parameters in any treatment group. Overall, tozorakimab demonstrated dose‐dependent systemic exposure in healthy Chinese participants and was well tolerated, with no safety concerns identified in this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dose-Response Relationship, DrugHealthy VolunteersAntibodies, Monoclonal, HumanizedHumansDouble-Blind MethodFemaleMaleAdultInjections, SubcutaneousYoung AdultMiddle AgedAdolescentChinaEast Asian People

Stichwörter der Autor:innen

Chinapharmacokineticssafetytozorakimab

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacologist, R&D China, AstraZeneca, Shanghai, China.
  • Department of Clinical Pharmacology, The First Affiliated Hospital of Soochow University, Soochow City, Jiangsu Province, China.
  • Clinical Development, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Barcelona, Spain.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Biostatistics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Zitieren

APA

Li, Y., Zhang, H., Pandya, H., Miao, L., Reid, F., Jimenez, E., Sadiq, M. W., Moate, R., Lei, A., Zhou, X. H., Kell, C., Ding, J., Zhang, G., Zhao, L., & Ge, X. (2024). A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1391

Vancouver

Li Y, Zhang H, Pandya H, Miao L, Reid F, Jimenez E, et al. A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1391

BibTeX
@article{Li2024,
  author = {Li, Yunfei and Zhang, Hua and Pandya, Hitesh and Miao, Liyan and Reid, Fred and Jimenez, Eulalia and Sadiq, Muhammad Waqas and Moate, Rachel and Lei, Alejhandra and Zhou, Xiao-Hong and Kell, Chris and Ding, Junjie and Zhang, Guanlin and Zhao, Lina and Ge, Xiaoyun},
  title = {A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1391}
}
Kostenlos starten →